Immunovant Inc 2026 annual report

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the ExchangeAct).Yes☐No☒ As of February2, 2026, there were 203,532,180 shares of the Registrant’s common stock, $0.0001 par value per share,outstanding. IMMUNOVANT, INC.QUARTERLY REPORT ON FORM 10-QFOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2025 PART I.FINANCIAL INFORMATION Item 1.Financial Statements (unaudited)Condensed Consolidated Balance Sheets as of December 31, 2025 and March31, 2025Condensed Consolidated Statements of Operations for the Three and Nine Months Ended December 31, 2025and 2024Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended December Where You Can Find More Information We make available free of charge on our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports onForm 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities andExchange Commission. In addition, investors and others should note that we may announce material business and financial informationto our investors using our investor relations website (www.immunovant.com), filings we make with the Securities and ExchangeCommission, webcasts, press releases, and conference calls. We use these mediums, including our website, to communicate with our The information contained on the website referenced in this Quarterly Report on Form 10-Q is not incorporated by reference into thisfiling, and the website address is provided only as an inactive textual reference. All trademarks, trade names, service marks, and copyrights appearing in this Quarterly Report on Form 10-Q are the property of theirrespective owners. IMMUNOVANT, INC.Condensed Consolidated Statements of Operations IMMUNOVANT, INC.Condensed Consolidated Statements of Comprehensive Loss IMMUNOVANT, INC.Condensed Consolidated Statements of Stockholders’ Equity(Unaudited, in thousands except share data) IMMUNOVANT, INC.Condensed Consolidated Statements of Cash Flows IMMUNOVANT, INC.Notes to Unaudited Condensed Consolidated Financial Statements Note 1 — Description of Business and Liquidity [A] Description of Business Immunovant, Inc. (together with its wholly-owned subsidiaries, the “Company” or “Immunovant”) is a clinical-stage immunologycompany dedicated to enabling normal lives for people with autoimmune diseases. The Company is pursuing a broad anti-FcRN (asdefined below) strategy based on its lead asset, IMVT-1402. The Company’s innovative product pipeline includes its productcandidates, IMVT-1402 and batoclimab (formerly referred to as IMVT-1401), both of which are novel, fully human, monoclonalantibodies that target the neonatal fragment crystallizable receptor (“FcRn”). Designed to be optimized as simple, subcutaneous [B] Liquidity The Company has incurred significant losses and negative cash flows from operations since its inception. As of December31, 2025, theCompany’s cash and cash equivalents totaled $994.5 million and its accumulated deficit was $1,597.3 million. The Company has not generated any revenues to date and does not anticipate generating any revenues unless and until it successfullycompletes development and obtains regulatory approval for IMVT-1402, batoclimab or any future product candidate. Management The Company intends to raise such additional capital through the issuance of equity securities, debt financings, potential collaboration,license or development agreements or other sources in order to further implement its business plan. However, if such financing is not Note 2 — Summary of Significant Accounting Policies [A] Basis of Presentation The Company’s fiscal year ends on March 31, and its first three fiscal quarters end on June 30, September 30, and December 31,respectively. The accompanying condensed consolidated financial statements are unaudited. The unaudited condensed consolidatedfinancial statements of the Company have been pr